CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome

Background Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic s...

Full description

Bibliographic Details
Main Authors: Yi Xiao, Ying Wang, Jianfeng Zhou, Yang Cao, Jin Wang, Li Zhu, Di Wang, Na Wang, Bin Xu, Liting Chen, Xiaolu Long, Jia Gu, Yaoyao Lou, Chunrui Li, Gaoxiang Wang, Haiyun An, Min Xiao
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000364.full

Internet

https://jitc.bmj.com/content/8/1/e000364.full

Similar Items